who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Eli Lilly (LLY) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Oct 29

Net income

$6,451M

up 15.5% y/y

Revenue

$24,397M

up 38.6% y/y

Operating income

$8,608M

up 16.9% y/y

Next report

~ Feb 3

not announced yet

The quarter in brief

Revenue rose 39% to $24.4 billion, and operating income grew 17% to $8,608 million. Diluted EPS rose 16% to $7.22 from $6.21.

Key growth driver: Revenue growth of +39% y/y — the report gives no segment split, so the driver is the whole business. · by the Q3 2026 report

Revenue by product ↓

All figures in $M.

Sankey diagram of LLY (Eli Lilly) earnings report for Q3 2026: revenue, costs and profitRevenue$24,397 · +38.6%Cost of sales$3,933 · +30.8%Research anddevelopment$4,247 · +22.5%Marketing,selling, andadministrative$3,125 · +14.0%Acquired IPR&D$4,181 · +537%Asset impairment,restructuring andother specialcharges$303 · −17.0%Operating income$8,608 · +16.9%35.3% marginNet interestincome (expense)$316 · +177%Net other income(expense)$114 · vs a $18 lossIncome beforeincome taxes$8,406 · +16.2%Income tax expense$1,955 · +18.5%23.3% effective rateNet income$6,451 · +15.5%$7.22/sh · 26.4% margin
Sankey diagram of LLY (Eli Lilly) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Revenue$24,397 · +38.6%
Cost of sales$3,933 · +30.8%
Research and development$4,247 · +22.5%
Marketing, selling, and administrative$3,125 · +14.0%
Acquired IPR&D$4,181 · +537%
Asset impairment, restructuring and other special charges$303 · −17.0%
Operating income$8,608 · +16.9% · 35.3% margin
Net interest income (expense)$316 · +177%
Net other income (expense)$114 · vs a $18 loss
Income before income taxes$8,406 · +16.2%
Income tax expense$1,955 · +18.5% · 23.3% effective rate
Net income$6,451 · +15.5% · $7.22/sh · 26.4% margin

Verdict: Revenue rose 39% to $24.4 billion, and operating income grew 17% to $8,608 million. Diluted EPS rose 16% to $7.22 from $6.21.

Full-year 2026 revenue guidance was raised to $91 to $92 billion from $85 to $87 billion. Non-GAAP EPS guidance was cut to $35.00 to $36.00 from $35.50 to $36.50. The dividend paid per share was $1.73 in Q3 2026, up 15% from $1.50.

Source and notation

Source: Eli Lilly and Company press release, 8-K EX-99.1 of 10/29/2026 (SEC EDGAR).

Open as an image: Eli Lilly (LLY), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Eli Lilly (LLY) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/lly. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/lly"><img src="https://whoreportstoday.com/t/lly/img/eli-lilly-and-company-lly-earnings-sankey.png" alt="Eli Lilly (LLY) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/lly">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/lly/img/eli-lilly-and-company-lly-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/lly">Eli Lilly (LLY) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. · Text: Wikipedia, CC BY-SA 4.0, abridged

Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. Market share (US pharma & biotech): ≈11% by TTM revenue.

Heads-up

Company reports

Q3 2026latest breakdownRevenue rose 39% to $24.4 billion, and operating income grew 17% to $8,608 million. Diluted EPS rose 16% to $7.22 from…
Q2 2026Record quarter — +48% on volume (+60%) with deliberate price cuts (−13%)

Revenue by product

Quarter · Sep 30, 2026

Product$ millionsY/Y
Net product revenue22,650+38.7%
Collaboration and other revenue1,747+37.6%

SEC EDGAR ↗

Fiscal year · Dec 31, 2025

Product$ millionsY/Y
Net product revenue60,958+49.6%
Collaboration and other revenue4,221-1.7%

10-K / 20-F ↗

How we calculate

Year-over-year change uses the comparable prior-year period. When the fourth quarter is calculated from the year and nine months, both filings are linked.

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $91–92Brevenue $65.2BEPS (GAAP) $22.95revenue +40…41%

Same quarter a year ago (ended December 31, 2025): revenue $19.3B, EPS (GAAP) $7.39

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +40%).

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

LLY earnings history: past report dates

Oct 29, 2026 Thu7:03 ambefore market openSep 30, 2026$24.4B+39% y/y$7.22+16% y/y
Aug 5, 2026 Wed7:05 ambefore market openJun 30, 2026$23.0B+48% y/y$7.94+26% y/y
Apr 30, 2026 Thu7:03 ambefore market openMar 31, 2026$19.8B+56% y/y$8.26+170% y/y
Feb 4, 2026 Wed7:05 ambefore market openDec 31, 2025≈$19.3B+43% y/y≈$7.39+51% y/y
Oct 30, 2025 Thu7:03 ambefore market openSep 30, 2025$17.6B+54% y/y$6.21+480% y/y
Aug 7, 2025 Thu7:05 ambefore market openJun 30, 2025$15.6B+38% y/y$6.29+92% y/y
May 1, 2025 Thu7:03 ambefore market openMar 31, 2025$12.7B+45% y/y$3.06+23% y/y
Feb 6, 2025 Thu7:05 ambefore market openDec 31, 2024≈$13.5B+45% y/y≈$4.88+102% y/y
Oct 30, 2024 Wed7:05 ambefore market openSep 30, 2024$11.4B+20% y/y$1.07
Aug 8, 2024 Thu7:04 ambefore market openJun 30, 2024$11.3B+36% y/y$3.28+68% y/y
Apr 30, 2024 Tue7:04 ambefore market openMar 31, 2024$8.8B+26% y/y$2.48+66% y/y
Feb 6, 2024 Tue7:04 ambefore market openDec 31, 2023≈$9.4B+28% y/y≈$2.42+13% y/y
Nov 2, 2023 Thu7:02 ambefore market openSep 30, 2023$9.5B+37% y/y−$0.06
Aug 8, 2023 Tue7:01 ambefore market openJun 30, 2023$8.3B+28% y/y$1.95+86% y/y
Apr 27, 2023 Thu7:02 ambefore market openMar 31, 2023$7.0B−11% y/y$1.49−29% y/y
Feb 2, 2023 Thu7:13 ambefore market openDec 31, 2022≈$7.3B−9% y/y≈$2.14+13% y/y
Nov 1, 2022 Tue7:03 ambefore market openSep 30, 2022$6.9B+2% y/y$1.61+32% y/y
Aug 4, 2022 Thu7:05 ambefore market openJun 30, 2022$6.5B−4% y/y$1.05−31% y/y
Apr 14, 2022 Thu4:57 pmafter market closeMar 31, 2022$7.8B+15% y/y$2.10+41% y/y
Feb 3, 2022 Thu7:08 ambefore market openDec 31, 2021≈$8.0B+8% y/y≈$1.89−19% y/y
Oct 26, 2021 Tue7:06 ambefore market openSep 30, 2021$6.8B+18% y/y$1.22−8% y/y
Aug 3, 2021 Tue7:37 ambefore market openJun 30, 2021$6.7B+23% y/y$1.53−1% y/y
Apr 27, 2021 Tue6:48 ambefore market openMar 31, 2021$6.8B+16% y/y$1.49−7% y/y
Jan 29, 2021 Fri6:32 ambefore market openDec 31, 2020≈$7.4B+22% y/y≈$2.32+41% y/y
Oct 27, 2020 Tue7:50 ambefore market openSep 30, 2020$5.7B+5% y/y$1.33−3% y/y
Jul 30, 2020 Thu7:03 ambefore market openJun 30, 2020$5.5B−2% y/y$1.55+8% y/y
Apr 23, 2020 Thu8:02 ambefore market openMar 31, 2020$5.9B+15% y/y$1.60−63% y/y
Jan 30, 2020 Thu6:29 ambefore market openDec 31, 2019$6.1B+8% y/y$1.64+49% y/y
Oct 23, 2019 Wed7:28 ambefore market openSep 30, 2019$5.5B+3% y/y$1.37+22% y/y
Jul 30, 2019 Tue11:27 amduring market hoursJun 30, 2019$5.6B+1% y/y$1.44
Apr 30, 2019 Tue1:31 pmduring market hoursMar 31, 2019$5.1B+3% y/y$4.31+272% y/y
Feb 6, 2019 Wed9:48 amduring market hoursDec 31, 2018$5.6B−8% y/y$1.10
Nov 6, 2018 Tue7:03 ambefore market openSep 30, 2018$5.3B−6% y/y$1.12+111% y/y
Jul 24, 2018 Tue6:45 ambefore market openJun 30, 2018$5.6B−4% y/y−$0.25
Apr 24, 2018 Tue6:44 ambefore market openMar 31, 2018$5.0B−5% y/y$1.16
Jan 31, 2018 Wed8:32 ambefore market openDec 31, 2017$6.2B+7% y/y−$1.58
Oct 24, 2017 Tue6:30 ambefore market openSep 30, 2017$5.7B+9% y/y$0.53−27% y/y
Jul 25, 2017 Tue6:36 ambefore market openJun 30, 2017$5.8B+8% y/y$0.95+34% y/y
Apr 25, 2017 Tue6:28 ambefore market openMar 31, 2017$5.2B+7% y/y−$0.10
Jan 31, 2017 Tue8:54 ambefore market openDec 31, 2016$5.8B+7% y/y$0.73+62% y/y
Oct 25, 2016 Tue6:28 ambefore market openSep 30, 2016$5.2B+5% y/y$0.73−3% y/y
Jul 26, 2016 Tue6:25 ambefore market openJun 30, 2016$5.4B+9% y/y$0.71+27% y/y
Oct 22, 2015 Thu6:25 ambefore market openSep 30, 2015$5.0B+2% y/y$0.75+60% y/y
Jul 23, 2015 Thu8:26 ambefore market openJun 30, 2015$5.0B+1% y/y$0.56−18% y/y
Apr 23, 2015 Thu6:42 ambefore market openMar 31, 2015$4.6B−1% y/y$0.50−26% y/y
Jan 30, 2015 Fri8:06 ambefore market openDec 31, 2014$5.1B−12% y/y$0.40−40% y/y
Oct 23, 2014 Thu6:41 ambefore market openSep 30, 2014$4.9B−16% y/y$0.47−58% y/y
Jul 24, 2014 Thu6:36 ambefore market openJun 30, 2014$4.9B−17% y/y$0.68−39% y/y
Apr 24, 2014 Thu6:41 ambefore market openMar 31, 2014$4.7B−16% y/y$0.68−52% y/y
Jan 7, 2014 Tue7:02 ambefore market openDec 31, 2013$5.8B−2% y/y$0.67−9% y/y
Oct 23, 2013 Wed6:36 ambefore market openSep 30, 2013$5.8B+6% y/y$1.11−6% y/y
Jul 24, 2013 Wed6:37 ambefore market openJun 30, 2013$5.9B+6% y/y$1.11+34% y/y
Apr 24, 2013 Wed6:34 ambefore market openMar 31, 2013$5.6B+0% y/y$1.42+56% y/y
Jan 29, 2013 Tue6:36 ambefore market openDec 31, 2012$6.0B−1% y/y$0.74−4% y/y
Oct 24, 2012 Wed6:34 ambefore market openSep 30, 2012$5.4B−11% y/y$1.18+6% y/y
Show all 55 reports since 2012Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Eli Lilly: 15-year financials

202565,17920,6408,9725,384
202445,04310,5903,7604,680
202334,1245,2407924,069
202228,5416,2455,7313,536
202128,3185,5826,0563,087
202024,5406,1945,1122,687
201922,3208,3183,8032,410
201821,4933,2324,3142,312
201719,974−2044,5392,192
201621,2222,7383,8142,159
201519,9592,4081,8982,127
201419,6162,3913,2962,101
201323,1134,6854,7232,121
201222,6034,0894,3992,187
201124,2874,3486,5632,180

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. New annual filings are checked in the nightly SEC refresh. The filing history starts in 2011. Where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Eli Lilly: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
20252025-12-31112,47626,53542,5037,26855,62935,228
202478,71514,27233,8123,26832,74028,376
202364,00610,77225,2942,81925,72727,293
202249,49010,65016,3132,06718,03517,138
202148,8068,97916,7413,81918,45215,053
202046,6335,64216,3493,65717,46212,482
201939,2862,60715,1332,33813,71011,775
201843,9089,82910,7987,32120,55011,888
201744,98111,59216,3446,53619,20214,536
201638,80614,00810,3054,58215,10110,987
201535,56914,5717,9793,66612,5748,230
201436,30815,37310,7023,87211,9289,741
201335,24917,6316,2263,83013,1058,917
201234,39914,7655,5434,01913,0398,390
201133,66013,5428,5045,92314,2488,931

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual figures use SEC XBRL. The nightly SEC check adds balance sheets from new annual filings. Earlier years use the screener’s filing history. Amounts use the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow, 1 year

YearCFO · Operating cash flowCAPEX · Capital expenditureFCF · Free cash flowcalculatedFCF margin, %calculatedDividends paidShare buybacksFCF / net income, %calculatedCFI · Investing cash flowCFF · Financing cash flow
20252025-12-3116,813————4,108—−10,972−2,213
More detailsHide details

$ millions, per fiscal year; ratios in %. “—” — no verified data or calculation not applicable.

* Sources
How we calculate

CFO, CFI and CFF are net operating, investing and financing cash flows. CAPEX is a positive cash outflow for capital expenditure; its scope follows the issuer document line. FCF = CFO − CAPEX; lease repayments are not deducted separately. If no separately sourced numeric CAPEX amount is available, CAPEX and FCF calculations are omitted. FCF margin = FCF / same-year revenue × 100. FCF / net income = FCF / same-year income attributable to shareholders × 100; losses or zero income produce a dash. Revenue and income use this card’s indicators table; missing or mismatched periods produce no ratio. Dividends and common share buybacks are actual annual cash payments from the cash flow statement, shown as positive cash outflows; payments to noncontrolling interests and share-compensation withholding taxes are excluded. Zero requires document evidence. Buybacks appear only if at least one reviewed payment exists in the fifteen-year window. The window is fifteen years; years without a single value are omitted. All listed years stay open; CFI, CFF and buybacks for Russia and Kazakhstan appear under More details.

Snapshot reviewed: . Updated after annual filings and three checks against issuer documents. Unreviewed and interim periods are excluded from the annual series.

More: latest reported period

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated27,42013,588+13,832
· incl. D&A (non-cash add-back)depreciation & amortization1,5881,411
· incl. stock-based comp (non-cash)share-based compensation562490
Investing activities, netcapex, acquisitions, securities−27,611−8,169−19,442
Financing activities, netdebt, buybacks, dividends−2,263666−2,929
· incl. buybacksrepurchases of common stock−4,334−2,600−1,734
· incl. dividends paid−4,635−4,039−596
FX effect on cash71439−368
Net change in cash−2,3836,524−8,907

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Dividends

$6.23 per share · 2025 ↗

Dividend history
Year$ per sharePaid, $ millions
20256.235,384
20245.44,680
20234.694,069
20224.073,535.8
20213.533,086.8
20203.072,687.1
20192.682,409.8
20182.332,311.8
20172.122,192.1
20162.052,158.5
2015—2,127.3
2014—2,101.2
2013—2,120.7
2012—2,187.4
20111.962,180.1

Per-share amounts are split-adjusted. Total payments come from the annual filings. SEC annual filings ↗

Shares outstanding and buybacks

943.36 million shares · Feb 9, 2026 ↗

4,108 million USD spent on buybacks · 2025 ↗

Share counts and buybacks by year
YearMillion sharesBuybacks, $ millions
2025Feb 9, 2026943.364,108
2024Feb 14, 2025948.17—
2023Feb 16, 2024950.16—
2022Feb 17, 2023950.3—
2021Feb 18, 2022952.35—
2020Feb 12, 2021958.43—
2019Feb 13, 2020956.38—
2018Feb 13, 20191,035.42—
2017Feb 14, 20181,095.6—
2016Feb 13, 20171,103.35—
2015Feb 12, 20161,106.09—
2014Feb 13, 20151,111.1—
2013Feb 14, 20141,119.71—
2012Feb 15, 20131,134.41—
2011Feb 15, 20121,160.41—

Share counts are shown as of the date stated in each filing. Buybacks, new shares and splits can all change the count.

Industry comparison

MetricCompanyMedian
Net debt / EBITDA1.23×2.45×
Debt / Equity1.23×0.83×
Interest coverage40.00×3.09×
Current ratio1.39×2.35×
Gross margin83.7%61.5%
Operating margin40.8%18.3%
Net margin31.3%14.7%
ROE65.9%14.6%
ROA17.9%6.5%
Sample and sources

US pharma & biotech · median from 46 companies. Company figures use the last four quarters and the balance sheet at Sep 30, 2026. Industry snapshot dated Sep 1, 2026, using SEC calendar-year 2025 data. Latest annual filing ↗ · SEC XBRL revenue ↗ · SEC XBRL assets ↗

Shareholders’ equity at Sep 30, 2026: $40.3B (27% of total assets). Compare with other S&P 500 companies →

Corporate governance

2/2good

  • Feb 20262025 10-K: a single class of stock — LLY common; the legal proceedings section shows no shareholder disclosure suits or SEC investigations. sec.gov ↗
  • Dec 2025Dividend per share rose from $3.07 (2020) to $6.23 (2025); diluted share count fell 1.5% over 5 years. data.sec.gov ↗
1 more fact and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Apr 2008In the shareholder class action In re Eli Lilly Securities Litigation (Zyprexa, 2007), the court ruled in the company's favor in April 2008. sec.gov ↗

Scoring: 2.0, no deductions: single class of stock, share count −1.5% over 5 years, dividend raised every year, buybacks; the 2007 Zyprexa class action ended with a ruling in the company's favor (2008); the 2012 SEC penalty was under the FCPA, not a deduction

Share classes
Single class — LLY common stock on the NYSE (cover of 2025 10-K).
Dilution
Diluted share count 2020→2025 −1.5% (XBRL); SBC 1.0% of revenue — no deduction.
Disclosure
Full 10-K/10-Q reporting.
Dividends
Dividend per share raised every year: $3.07 (2020) → $6.23 (2025); buybacks of $0.75–4.1B a year.
Lawsuits & regulators
The 2025 10-K shows no shareholder disclosure suits or SEC cases; the 2007 shareholder suit (Zyprexa) ended with a ruling in Lilly's favor in April 2008; the 2012 SEC matter ($29.4M) was under the FCPA and is not deducted under the methodology.
Related parties
The 2026 proxy discloses no material related-party transactions; Lilly Endowment is a large shareholder with no special rights (single class of stock).

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Eli Lilly (LLY) earnings: FAQ

When is LLY's next earnings date?

We have not yet seen an announcement of the date from Eli Lilly (LLY). Based on last year's report on Feb 4, 2026, the next report is expected around Feb 3, 2027.

What time does LLY report earnings?

Eli Lilly usually reports before market open: its latest results release was filed with the SEC at 7:03 am ET on Oct 29, 2026.

When did LLY last report earnings?

Eli Lilly reported Q3 2026 results on Oct 29, 2026.

What has Eli Lilly guided for FY2026?

Company guidance for FY2026: revenue $91–92B. A year ago (FY2025): revenue $65.2B, EPS (GAAP) $22.95. Implied growth: revenue +40…41%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).

Where can I find Eli Lilly's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to LLY's filings; this page breaks the latest report down in a Sankey chart.

What was LLY's net income in Q3 2026?

Eli Lilly reported net income of $6,451M for Q3 2026 (+15.5% year over year), under US GAAP.

Does Eli Lilly pay dividends?

Yes. In 2025, Eli Lilly paid $5,384M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Eli Lilly's revenue changed since 2011?

Per its 10-K filings, revenue grew 2.7x: $24,287M in 2011 and $65,179M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy